Latest News
From the Journals
POSH study: BRCA mutations did not influence survival in young onset breast cancer
BRCA-positive and BRCA-negative women had similar overall survival at 2 years, 5 years, and 10 years after diagnosis.
Conference Coverage
VIDEO: Anticoagulant underprescribing common, jeopardizing atrial fib patients
Drug-prescribing data show many patients with atrial fibrillation are underdosed with anticoagulants, often due to fears about bleeding.
From the Journals
Children with pathogenic TP53 variants face increased risk of hard-to-treat ALL
Pathogenic TP53 variants could hold the key to identifying ALL patients with a poor prognosis.
From the Journals
Young e-cigarette users graduating to the real thing
Use of noncigarette forms of tobacco can be tantalizing.
From the Journals
Age at RRSO affects peritoneal cancer risk in BRCA mutation carriers
The risk was predominantly observed in BRCA1 mutation carriers, and disease development generally occurred within 5 years following RRSO.
Conference Coverage
AUDIO: Immunotherapy’s role in NHL
Dr. Stephen Ansell outlines the challenges in using immunotherapy effectively in non-Hodgkin lymphoma and future directions.
From the Journals
Phase 1 study: Human IL-10 plus checkpoint blockade looks promising in RCC, NSCLC
Pegylated human IL-10 + anti–PD-1 therapy is well tolerated and shows promise for the treatment of both RCC and NSCLC.
From the Journals
S-1 regimen noninferior to other frontline mCRC options
Frontline treatment with the oral fluoropyrimidine S-1 combined with irinotecan and bevacizumab was noninferior to other common regimens.
From the Journals
Pain after breast surgery may not be caused by the operation
The source of postop pain in breast surgery patients is not well understood.
From the Journals
In Brazil, few patients get second- and third-line treatment for metastatic RCC
Of 3,990 patients with mRCC, 79% received an appropriate first-line treatment, but only 20% went on to get a second-line agent.
From the Journals
Modeling study: Screening, treatment effects on breast cancer mortality vary by subtype
Breast cancer mortality reductions over time are associated with treatment and screening advances but vary by molecular subtype of disease.